AquaLiv Discusses Recent Events in Kenya Concerning its HIV-AIDS Treatment

Representatives from Infrared Systems International (OTCBB: IFRS) subsidiary, AquaLiv, Inc., have returned from Kenya with updates concerning their NatuRx™ HIV/AIDS treatment.

The company previously announced AquaLiv representatives would be visiting Kenya to make preparations for an upcoming clinical trial of NatuRx™ HIV/AIDS. According to the company, while attempting to register the treatment as a drug, Kenyan officials instead recommended filing as an alternative medicine.

"Unlike traditional drugs, all NatuRx™ treatments are information-based and do not rely on chemical interaction with active molecules to function," stated AquaLiv CEO, Craig Hoffman. "The Kenyan authorities recognized that our unique treatment has a negligible toxicity and cannot be misused. It is impossible to overdose. In our first regulatory organization experience with NatuRx™, the treatment was acknowledged and understood far easier than we anticipated."

Mr. Hoffman continued, "Even more exciting than this warm welcome is the outcome of an approved registration as an alternative medicine. If approved, we will be able to market and sell NatuRx™ HIV/AIDS without further clinical trials. And, approval could be granted in the next 30-60 days. The biggest hurdle in biotech is regulatory approval for sale and ongoing costs of continued clinical trials. This will be a big a win for AquaLiv."

In order to produce valuable data, the company intends to continue with the planned clinical trial even though it may not be needed to sell the treatment in Kenya. Several clinics and physicians were identified to participate in the trial. Required protocol is being discussed and budgets are being established for the various participants.

"Kenya is known as the 'Gateway to Africa' because other African nations usually follow suit," added Bill Wright, CEO of Infrared Systems International. "Achieving success in Kenya is generally a successful forecast for all of Africa."

Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment. The solutions have no contraindications, are non-toxic and resembles common mineral water in analysis.